Yesterday, Nov. 18, 2015, 127 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $235.29 to $228,091,773.00.

Highlighted Stocks Traded by Insiders:

2U (TWOU) - FREE Research Report

Macias Edward S., who is Director at 2U, bought 1,064 shares at $21.42 on Nov. 18, 2015. Following this transaction, the Director owned 9,496 shares meaning that the stake was boosted by 12.62% with the 1,064-share transaction.

The shares most recently traded at $22.18, up $0.76, or 3.43% since the insider transaction. Historical insider transactions for 2U go as follows:

  • 4-Week # shares bought: 738
  • 4-Week # shares sold: 23,640
  • 12-Week # shares bought: 738
  • 12-Week # shares sold: 23,640
  • 24-Week # shares bought: 738
  • 24-Week # shares sold: 23,640

The average volume for 2U has been 1.2 million shares per day over the past 30 days. 2U has a market cap of $967.6 million and is part of the technology sector and computer software & services industry. Shares are up 11.09% year-to-date as of the close of trading on Wednesday.

2U, Inc. provides cloud-based software-as-a-service (SaaS) solutions for nonprofit colleges and universities to deliver education to qualified students. Currently, there are 5 analysts who rate 2U a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TWOU - FREE

TheStreet Quant Ratings rates 2U as a sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow. Get the full 2U Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Sucampo Pharmaceuticals (SCMP) - FREE Research Report

Smith Andrew P, who is Chief Financial Officer at Sucampo Pharmaceuticals, bought 1,605 shares at $17.03 on Nov. 18, 2015. Following this transaction, the Chief Financial Officer owned 1,605 shares meaning that the stake was boosted by 100% with the 1,605-share transaction.

The shares most recently traded at $17.32, up $0.29, or 1.67% since the insider transaction. Historical insider transactions for Sucampo Pharmaceuticals go as follows:

  • 4-Week # shares sold: 1.6 million
  • 12-Week # shares sold: 1.6 million
  • 24-Week # shares sold: 1.6 million

The average volume for Sucampo Pharmaceuticals has been 1.0 million shares per day over the past 30 days. Sucampo Pharmaceuticals has a market cap of $765.4 million and is part of the health care sector and drugs industry. Shares are up 24.16% year-to-date as of the close of trading on Wednesday.

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research and development of proprietary drugs in the Americas, Europe, and Asia. The company has a P/E ratio of 23.8. Currently, there are 3 analysts who rate Sucampo Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SCMP - FREE

TheStreet Quant Ratings rates Sucampo Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and impressive record of earnings per share growth. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Sucampo Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Essent Group (ESNT) - FREE Research Report

Glanville Robert, who is Director at Essent Group, bought 1,000 shares at $23.10 on Nov. 18, 2015. Following this transaction, the Director owned 15,924 shares meaning that the stake was boosted by 6.7% with the 1,000-share transaction.

The shares most recently traded at $23.83, up $0.73, or 3.06% since the insider transaction. Historical insider transactions for Essent Group go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 8,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 8,000
  • 24-Week # shares bought: 4,000
  • 24-Week # shares sold: 12,000

The average volume for Essent Group has been 485,200 shares per day over the past 30 days. Essent Group has a market cap of $2.2 billion and is part of the financial sector and real estate industry. Shares are down 8.21% year-to-date as of the close of trading on Wednesday.

Essent Group Ltd., through its subsidiaries, provides private mortgage insurance and reinsurance for mortgages secured by residential properties located in the United States. The company has a P/E ratio of 15.0. Currently, there are 4 analysts who rate Essent Group a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ESNT - FREE

TheStreet Quant Ratings rates Essent Group as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, expanding profit margins, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Essent Group Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Data for this article provided by Zacks Investment Research